Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
10.1007/s10787-024-01603-y 17 De GiorgiR.GhenciulescuA.DziwiszO.TaquetM.AdlerA
Leading obesity medicine societies now classify obesity as a chronic disease, and GLP-1 treatment as potentially long-term management, similar to statins for cholesterol or antihypertensives for blood pressure
Scenario 2: Private Insurance Without Manufacturer Program Profile: 38-year-old with basic private insurance (Blue Cross), BMI 32, no other conditions Coverage: Insurance covers obesity medications but with $3,000 annual cap, 20% copay Calculation: Annual retail cost: $21,000 Insurance pays up to $3,000 (their maximum) Patient owes remaining $18,000 Patient cant access manufacturer program (no insurance coverage for balance) Final patient cost: $18,000 annually ($1,500/month) Verdict: Insurance caps make this scenario barely better than no coverage
A sensitivity analysis excluding the ITCA trial reported a similar reduction in MACE as the pooled analysis (HR (95%CI): 0.86 (0.810.90)
Necroptosis also induces macrophage IL-6 production, which upregulates CD47 on tumor cells, allowing immune evasion and driving liver metastasis and therapeutic resistance
US$ 21.73
US$ 21.96
US$ 29.18
US$ 20.26
US$ 20.15
US$ 24.20
US$ 20.67
US$ 27.93
US$ 20.75
US$ 27.68
US$ 22.45
US$ 28.20
